The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IBC 2025 | Wrap-up of the 2025 Intercepting Blood Cancers Workshop
Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, shares the success of the 2025 Intercepting Blood Cancers (IBC) Workshop. She notes the value of sharing knowledge between early precursors of myeloma, lymphoma, and leukemia, and highlights that the meeting covers basic science, translational research, and clinical trials. This interview took place at the 3rd Intercepting Blood Cancers (IBC) Workshop held in Nice, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So this was our third IBC meeting, Interception of Blood Cancer, and it keeps getting better and better. It was just amazing to see everyone come together between the early precursors of myeloma, lymphoma, and leukemia, talking about what is common between us and what are the differences and learning from each other. And it was both basic science, translational research and clinical trials...
So this was our third IBC meeting, Interception of Blood Cancer, and it keeps getting better and better. It was just amazing to see everyone come together between the early precursors of myeloma, lymphoma, and leukemia, talking about what is common between us and what are the differences and learning from each other. And it was both basic science, translational research and clinical trials. We had also the pharma partners. We had our foundation with Jenny. And of course, we would love to have the FDA come back and work with us. And together, we really think of what is the future of early detection, risk stratification, but also interception. And the hope at the end of all of this is that we are curing our patients before they get symptoms.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
